{"id":3691,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amsacrine-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amsacrine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amsacrine-txt\/","title":{"rendered":"Amsacrine.txt"},"content":{"rendered":"

Amsacrine<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:
\nAcute leukaemias<\/p>\n

DOSE IN NORMAL RENAL FUNCTION <\/H3><\/p>\n
  • Induction of remission: 90\u2013120 mg\/m\n

    2
    \ndaily for 5\u20138 days, repeated at 2\u20134 week
    \nintervals according to response<\/p>\n

  • Maintenance: 150 mg\/m\n

    2 as a single dose
    \nor divided over 3 consecutive days every
    \n3\u20134 weeks<\/p>\n

  • Or according to local policy\n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n393.5\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n96\u201398\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n2\u201310\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n1.67\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n5\u20138\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : 60\u201375 mg\/m2 daily
    \n
  • 10 to 20 &nbsp &nbsp : 60\u201375 mg\/m2 daily
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n60\u201375 mg\/m2 daily
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nUnlikely to be dialysed. Dose as in
    \nGFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nUnlikely to be dialysed. Dose as in
    \nGFR <10 mL\/min
    \n
  • HDF\/high flux &nbsp :
    \nUnlikely to be dialysed. Dose as in
    \nGFR <10 mL\/min
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nGFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs
    \nNone known<\/p>\n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nIV<\/p>\n

    Rate of Administration <\/H4>
    \n60\u201390 minutes<\/p>\n

    Comments<\/H4>
    \nDilute in 500 mL of glucose 5%<\/p>\n

    Use glass syringes<\/p>\n

    Incompatible with sodium chloride<\/p>\n

    OTHER INFORMATION <\/H4><\/p>\n
  • Increased risk of side effects in renal\n

    impairment<\/p>\n

  • Amsacrine is extensively metabolised in\n

    the liver. The principal metabolites, via
    \nmicrosomal oxidation, are much more
    \ncytotoxic than the parent drug. Excretion
    \nis via the bile; >50% excreted in faeces
    \nwithin 2 hours; 35% in urine<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amsacrine CLINICAL USE Antineoplastic agent: Acute leukaemias DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3691","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3691"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3691\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}